|
KMID : 0923620200200030027
|
|
Immune Network
2020 Volume.20 No. 3 p.27 ~ p.27
|
|
|
Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
|
|
Kang Da-Hyun
Park Cheol-Kyu
Chung Chae-Uk
Oh In-Jae
Kim Young-Chul
Park Dong-Il
Kim Jin-Hyun
Kwon Gye-Cheol
Kwon In-Sun
Sun Pu-Reum
Shin Eui-Cheol
Lee Jeong-Eun
|
|
|
Abstract
|
|
|
|
Although various studies on predictive markers in the use of PD-1/PD-L1 inhibitors are in progress, only PD-L1 expression levels in tumor tissues are currently used. In the present study, we investigated whether baseline serum levels of IL-6 can predict the treatment response of patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1/PD-L1 inhibitors. In our cohort of 125 NSCLC patients, the objective response rate (ORR) and disease control rate (DCR) were significantly higher in those with low IL-6 (<13.1 pg/ml) than those with high IL-6 (ORR 33.9% vs. 11.1%, p=0.003; DCR 80.6% vs. 34.9%, p<0.001). The median progression-free survival was 6.3 months (95% confidence interval [CI], 3.9?8.7) in the low IL-6 group, significantly longer than in the high IL-6 group (1.9 months, 95% CI, 1.6?2.2, p<0.001). The median overall survival in the low IL-6 group was significantly longer than in the high IL-6 group (not reached vs. 7.4 months, 95% CI, 4.8?10.0). Thus, baseline serum IL-6 levels could be a potential biomarker for predicting the efficacy and survival benefit of PD-1/PD-L1 inhibitors in NSCLC.
|
|
|
KEYWORD
|
|
|
IL-6, Lung cancer, Immunological antineoplastic agents, PD-1/PD-L1
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|
|